Anti-Aβ/Anti-TfR1: Trontinemab (RO7126209), an anti-Aβ/anti-TfR1 bispecific antibody, is currently in Phase II development (NCT04639050, Brainshuttle AD study) [75]. This evidence concerns the gene TFRC and Alzheimer disease.